Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. (Q38352171)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

review article

1 reference

title

Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

main subject

gram-positive bacteria

0 references

multiple drug resistance

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sheryl A. Zelenitsky

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Philippe Lagacé-Wiens

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

George G Zhanel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

15

James A Karlowsky

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

Riley Love

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Heather Adam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Frank Schweizer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Bala Gorityala

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Ethan Rubinstein

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Andrew Walkty

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Alfred S Gin

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Matthew Gilmour

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Daryl J Hoban

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Joseph P Lynch

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

253-270

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25673021%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40265-015-0352-7

29 February 2020

exact match

0 references

cites work

MRSA: the first half century

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid: a novel oxazolidinone for Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Methicillin-resistant Staphylococcus aureus: an evolving pathogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Current and prospective treatments for multidrug-resistant gram-positive infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Methicillin-resistant Staphylococcus aureus therapy: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Linezolid for the treatment of drug-resistant infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid: a new oxazolidinone antimicrobial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid (TR-701): a new oxazolidinone with enhanced potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Oxazolidinone Structure–Activity Relationships Leading to Linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Recent development of potent analogues of oxazolidinone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

The oxazolidinones: past, present, and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid for the management of human infections: in vitro characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Characterization and monitoring of linezolid-resistant clinical isolates of Staphylococcus epidermidis in an intensive care unit 4 years after an outbreak of infection by cfr-mediated linezolid-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Elevated linezolid resistance in clinical cfr-positive Staphylococcus aureus isolates is associated with co-occurring mutations in ribosomal protein L3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid population pharmacokinetics, exposure response, and target attainment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0352-7

Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25673021

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25673021

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25673021